Priority List of COVID-19 Adverse events of special interest

This deliverable provides the fifth update to the Priority List of potential Adverse events of special interest relevant to COVID-19 vaccine trials. Past updates focused on COVID-19 disease course and complications whereas this one shifts the emphasis to what has been observed for COVID-19 vaccines currently in use. It is limited to countries with pharmacovigilance programs in place that are able to monitor large populations (United States, Canada, Australia, United Kingdom, European Union).The SPEAC Project is funded in whole by CEPI